RiceBran Technologies (RIBT) AI Stock Analysis

• Market Cap: $1.00K
• Dividend Yield: N/A
• Average Volume (3M): 16.77K
• Price to Earnings (P/E): ―
• Beta (1Y): -2.47
• Revenue Growth: N/A
• EPS Growth: N/A
• Country: US
• Employees: 35
• Sector: Consumer Defensive
• Sector Strength: 44
• Industry: Packaged Foods
• EPS (TTM): -1.14
• Shares Outstanding: 10,004,002
• 10 Day Avg. Volume: 13,840
• 30 Day Avg. Volume: 16,766
• PEG Ratio: N/A
• Price to Book (P/B): 0.00
• Price to Sales (P/S): 0.00
• P/FCF Ratio: 0.00
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: N/A
• Price Target Upside: N/A
• Rating Consensus: N/A
• Number of Analyst Covering: 0

• Rating: 33 Underperform
• Price Target: ―

The overall score reflects RiceBran Technologies' significant financial difficulties, marked by declining revenues, negative equity, and high leverage. Incomplete technical analysis and poor valuation metrics further contribute to a low score. Lack of substantial earnings call insights or corporate events limits potential positive impact, underscoring the need for strategic and operational improvements.

RiceBran Technologies Business Overview & Revenue Model

Company Description

RiceBran Technologies, together with its subsidiaries, operates as a specialty ingredient company. It focuses on producing, processing, and marketing of value-added healthy, natural, and nutrient dense products derived from rice and other small grains. The company converts raw rice bran into stabilized rice bran (SRB) and high value derivative products, including RiBalance, a complete rice bran nutritional package derived from further processing of SRB; RiSolubles, a nutritious carbohydrate and lipid rich fraction of RiBalance; RiFiber, a protein and fiber rich insoluble derivative of RiBalance; and ProRyza products, which includes derivatives composed of protein and protein/fiber blends. Its SRB and derivative products are nutritional and beneficial food products that contain a combination of oil, protein, carbohydrates, vitamins, minerals, fibers, and antioxidants that enhance the nutritional value of consumer products. The company's SRB products are also marketed as feed ingredients in the animal nutrition markets. It serves food and animal nutrition manufacturers, wholesalers, and retailers in the United States and internationally. The company was formerly known as NutraCea and changed its name to RiceBran Technologies in October 2012. RiceBran Technologies was founded in 2000 and is headquartered in Tomball, Texas.

How the Company Makes Money

RiceBran Technologies generates revenue primarily through the sale of its rice bran-based ingredients and products. The company's key revenue streams include sales to the food and beverage industry, where its products are used as functional and nutritional ingredients, and the animal nutrition sector, where its offerings serve as feed additives. Additionally, RiceBran Technologies may form strategic partnerships to expand its market reach and product applications, although specific partnerships impacting revenue are undisclosed. The company's ability to innovate and develop new applications for its rice bran ingredients contributes to its earnings potential.

RiceBran Technologies Financial Statement Overview

Summary

RiceBran Technologies faces significant financial challenges: declining revenues from $41.6M in 2022 to $22.6M in 2023, consistent losses, and liquidity issues. Negative stockholders' equity and high leverage highlight potential financial instability. Minor improvements in cash flow do not offset overall weak financial health, necessitating strategic restructuring.

Income Statement

RiceBran Technologies has been experiencing a declining revenue trend with a notable revenue drop from $41.6M in 2022 to $22.6M in 2023. The company has consistently reported negative net income and gross profit margins over the years, indicating significant challenges in achieving profitability. EBIT and EBITDA margins are also negative, reflecting operational inefficiencies and declining performance.

Balance Sheet

The company's balance sheet reveals a negative stockholders' equity in 2023, indicating financial distress. The debt-to-equity ratio is not calculable due to negative equity, but high total liabilities relative to assets suggest high leverage, posing significant financial risk. The equity ratio has also worsened from 2019 to 2023.

Cash Flow

Free cash flow remains negative, though there is a slight improvement in operating cash flow in 2023 compared to previous years. However, the company has shown a consistent trend of negative free cash flow, indicating ongoing liquidity challenges. The operating cash flow to net income ratio is less informative due to persistent negative net income.

Breakdown	Dec 2023	Dec 2022	Dec 2021	Dec 2020	Dec 2019
Income Statement
Total Revenue	22.65M	41.62M	31.13M	26.20M	23.71M
Gross Profit	-411.00K	-759.00K	442.00K	-2.47M	-861.00K
EBITDA	-6.83M	-5.11M	-5.87M	-8.77M	-11.71M
Net Income	-8.97M	-7.86M	-8.95M	-11.73M	-14.87M
Balance Sheet
Total Assets	9.32M	27.43M	31.31M	34.80M	40.49M
Cash, Cash Equivalents and Short-Term Investments	1.14M	3.94M	5.83M	5.26M	8.44M
Total Debt	5.57M	9.86M	8.56M	8.33M	5.20M
Total Liabilities	12.32M	14.52M	12.82M	11.38M	8.75M
Stockholders Equity	-3.00M	12.91M	18.50M	23.42M	31.74M
Cash Flow
Free Cash Flow	-3.11M	-4.50M	-5.64M	-9.13M	-17.67M
Operating Cash Flow	-2.42M	-3.94M	-4.20M	-7.95M	-13.45M
Investing Cash Flow	990.00K	-454.00K	-798.00K	-919.00K	-8.47M
Financing Cash Flow	-1.37M	2.51M	5.56M	5.68M	23.10M

RiceBran Technologies Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
NATR	80 Outperform	$302.27M	22.98	9.15%	―	4.33%	-6.33%
MAMA	79 Outperform	$373.85M	82.60	17.44%	―	19.34%	-12.64%
LWAY	77 Outperform	$473.85M	45.23	14.46%	―	9.19%	-23.91%
Sector *	62 Neutral	$20.49B	14.73	-2.69%	3.15%	1.98%	-5.13%
STKL	60 Neutral	$764.66M	―	-1.34%	―	10.90%	96.02%
LSF	42 Neutral	$61.32M	―	-8.34%	―	22.79%	74.00%
RIBT	33 Underperform	$1.00K	―	299.17%	―	―	―